 |
|
 |
- December 1, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Insulin Resistance, Diabetes and Vascular Disease: The Emerging Role of Glitazones"Prof. Nikolaus Marx (biography)
English - 2006-05-06 - 41 minutes
|
 | (56 slides) |
Summary :
Insulin resistance is associated with several cardiovascular risk factors. In this presentation Prof. Marx focuses on inflammation, endothelial dysfunction and arteriosclerosis, and evidence for how they can be improved with glitazone treatment.
The insulin-sensitising glitazones work by activating the nuclear transcription factor PPARγ. They are known to reduce inflammation and improve endothelial function in type 2 diabetic patients, however these effects have also been observed in nondiabetic individuals (1,2), suggesting that these effects of TZDs are independent of their metabolic effects.
Glitazones also appear to cause morphological changes in the vessel wall. For example, in type 2 diabetic patients with coronary artery disease, rosiglitazone was found to reduce instent-restenosis (3). Is this effect independent of the drug's glucose-lowering effect? Of interest is that in nondiabetic patients with coronary artery disease, pioglitazone treatment for 6 months after coronary stent implantation was found to reduce neointima volume (4). Prof. Marx also presents some new findings from a study of nondiabetic patients with symptomatic coronary artery stenosis who were randomised to rosiglitazone or placebo 4 weeks before undergoing endarterectomy. Plaque specimens were obtained from the surgery and studied, and rosiglitazone treatment was found to significantly reduce vascular inflammation in these patients, leading to a more stable type of arteriosclerotic lesion (1).
Copyright © 2006 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Effects of glitazone treatment on inflammation, endothelial function and arteriosclerosis in type 2 diabetic patients and nondiabetic individuals
Bibliographic references :
1. Franz Meisner; Daniel Walcher; Florence Gizard; Xaver Kapfer; Roman Huber; Anja Noak; Ludger Sunder-Plassmann; Helga Bach; Cornelia Haug; Max Bachem; Tatjana Stojakovic; Winfried März; Vinzenz Hombach; Wolfgang Koenig; Bart Staels; Nikolaus Marx. Effect of Rosiglitazone Treatment on Plaque Inflammation and Collagen Content in Nondiabetic Patients: Data From a Randomized Placebo-Controlled Trial Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:845.
2. Jürgen Hetzel; Bernd Balletshofer; Kilian Rittig; Daniel Walcher; Wolfgang Kratzer; Vinzenz Hombach; Hans-Ulrich Häring; Wolfgang Koenig; Nikolaus Marx Rapid Effects of Rosiglitazone Treatment on Endothelial Function and Inflammatory Biomarkers Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1804.
3. Donghoon Choi, MD, PHD, Soo-Kyung Kim, MD, Sung-Hee Choi, MD, Young-Guk Ko, MD, Chul-Woo Ahn, MD, PHD, Yangsoo Jang, MD, PHD, Sung-Kil Lim, MD, PHD, Hyun-Chul Lee, MD, PHD and Bong-Soo Cha, MD, PHD. Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes Diabetes Care 27:2654-2660, 2004.
4. Nikolaus Marx, MD; Jochen Wöhrle, MD; Thorsten Nusser, MD; Daniel Walcher, MD; Angelika Rinker, MS; Vinzenz Hombach, MD; Wolfgang Koenig, MD; Martin Höher, MD. Pioglitazone Reduces Neointima Volume After Coronary Stent Implantation: A Randomized, Placebo-Controlled, Double-Blind Trial in Nondiabetic Patients Circulation. 2005;112:2792-2798.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
